glp 1 litigation GLP-1 Receptor Agonist Litigation: MDL 3094 Navigating The GLP-1 Litigation Landscape

46 Native oxyntomodulin also significantly augments glucose-dependent insulin secretion acutely in subjects with obesity, with and without diabetes

However, a significant correlation was not observed for the AUCGLP-1 DBP relationship (Panel B)

, Mller, M

GLP-1 isnt just an incretin - its a full gutbrainpancreas signaling axis

The three year absolute risk was 2.4% (95% CI 2.1% to 2.7%) lower for SGLT-2 inhibitors than DPP-4 inhibitors (4.6% v 7.0%), 1.8% (1.4% to 2.1%) lower for GLP-1 receptor agonists than DPP-4 inhibitors (5.7% v 7.5%), and 1.2% (0.9% to 1.5%) lower for SGLT-2 inhibitors than GLP-1 receptor agonists (4.7% v 6.0%)